Bayer AG (ETR:BAYN), the German pharmaceutical giant, has experienced a string of
financial and
legal challenges recently, causing its share price to
plummet by 49% within a year. Negative developments include a
dividend cut to address its
debt burden, a failed drug trial and ongoing lawsuits related to its
Roundup weedkiller. Bayer's stock also had its worst day in over a decade, and dropped to an 18-year low after the termination of the asundexian trial. However, the company has had occasional
wins, as witnessed by the stock jump following Monsanto's appeal victory on a PCB verdict. Bayer's major shareholder Harris has endorsed the CEO's plan for
internal restructuring, despite significant investor pressure. The company is focussing on job cuts and letting its employees 'self-organize' to save $2.15 billion. Meanwhile, recent developments in its portfolio have sparked new interest, notably, Bayer AG becoming a key player in Kahn Brothers' Portfolio with a 1.04% stake.
BAYER Stocks News Analytics from Wed, 08 Nov 2023 08:00:00 GMT to Sun, 26 May 2024 08:46:09 GMT -
Rating -8
- Innovation -5
- Information 8
- Rumor -6
